Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective and Retrospective Observational/Non-interventional Study to Characterize Biomarkers and Disease Progression in Patients With MECP2 Duplication Syndrome

NCT06014541 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06014541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06014541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective and Retrospective Observational/Non-interventional Study to Characterize Biomarkers and Disease Progression in Patients With MECP2 Duplication Syndrome
Lead sponsor
Ionis Pharmaceuticals, Inc.
Phase
Observational
Overall status
Terminated
Start date
October 3, 2023
Completion date
October 7, 2025
Enrollment
29 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

methyl cpg binding protein 2 (mecp2) duplication syndrome